A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence

Archives of General Psychiatry

Volumn 56, Issue 8, 1999, Pages 719-724

  Mason, Barbara J ^a,b   Salvato, Fernando R ^a   Williams, Lauren D ^a   Ritvo, Eva C ^a   Robert B, Cutler ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Alcohol Disorders Research Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISULFIRAM; NALMEFENE; NALTREXONE; OPIATE ANTAGONIST; PLACEBO;

ABSTINENCE; ADULT; ALCOHOLISM; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEARTBURN; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; TACHYCARDIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ALCOHOL DRINKING; ALCOHOLISM; BREATH TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETHANOL; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; PLACEBOS; RECURRENCE; TEMPERANCE; TREATMENT OUTCOME;

EID: 0032765495     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.56.8.719     Document Type: Article

References (41)

1. Meyer RE. Prospects for a rational pharmacotherapy of alcoholism. J Clin Psychiatry. 1989;50:403-412.
2. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I, Manny I, Neiderhiser D, Nocks JJ, Shaw S. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA. 1986;256:1449-1455.
3. Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs. 1997;53:1038-1053.
4. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
5. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881-887.
6. Croop RS, Faulkner EB, Labriola DF, for the Naltrexone Usage Study Group. The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. Arch Gen Psychiatry. 1997;54:1130-1135.
7. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, O'Brien CP. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry. 1997;54:737-742.
8. Oslin D, Liberto JG, O'Brien J, Krois S, Norbeck J. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry. 1997;5:324-332.
9. O'Malley SS, Jaffe AJ, Chang G, Rode S, Schottenfeld R, Meyer RE, Rounsaville B. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry. 1996;53:217-224.
10. Physicians' Desk Reference. 51st ed. Montvale, NJ: Medical Economics Co; 1997: 957-959.
11. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res. 1994;18:1162-1167.
12. Fudala PJ, Heishman SJ, Henningfield JE, Johnson RE. Human pharmacology and abuse potential of nalmefene. Clin Pharmacol Ther. 1991;49:300-306.
13. Dixon R, Howes J, Gentile J. Nalmefene: intravenous safety and kinetics of a new opioid antagonist. Clin Pharmacol Ther. 1986;39:49-53.
14. Gal TJ, Difazio CA, Cosmo A, Dixon R. Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther. 1986;40:537-542.
15. Gal SJ, Difazio CA. Prolonged antagonism of opioid action with intravenous nalmefene. Anesthesiology. 1986;64:175-180.
16. Wall ME, Brine DR, Perez-Reyes M. Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Dispos. 1981;9:369-375.
17. Dixon R, Gentile J, Hsu HB, Hsiao J, Howes J, Garg D, Weidler D. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol. 1987;27:233-239.
18. Wilhelm JA, Veng-Pedersen P, Zakszewski TB, Osifchin E, Waters SJ. Duration of opioid antagonism by nalmefene and naloxene in the dog: a nonparametric pharmacodynamic comparison based on generalized cross-validated spline estimation. Int J Clin Pharmacol Ther. 1995;33:540-545.
19. Tabakoff B, Hoffman PL. Alcohol interactions with brain opiate receptors. Life Sci. 1983;32:197-204.
20. Charness ME, Gordon AS, Diamond I. Ethanol modulation of opiate receptors in cultured neural cells. Science. 1983;222:1246-1248.
21. Michel ME, Bolger G, Weissman BA. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol. 1985;7:175-177.
22. Emmerson PJ, Liu M, Woods JH, Medzihradsky F. Binding affinity and selectivity of opioids at mu, delta, and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther. 1994;271:1630-1637.
23. Culpepper-Morgan JA, Holt PR, LaRoche D, Kreek MJ. Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig. Life Sci. 1995;56:1187-1992.
24. Sawynok J, Pinsky C, LaBella FS. On the specificity of naloxone as an opiate antagonist. Life Sci. 1975;25:1621-1632.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
26. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? a novel assessment technique. JAMA. 1989;261:3273-3277.
27. Rudd P, Ahmed S, Zachary V, Barton C, Bonduelle D. Compliance with medication timing: implications from a medication trial for drug development and clinical practice. J Clin Res Pharmacoepidemiol. 1992;6:15-27.
28. Kadden RM, Carroll K, Donovan DM, Cooney N, Monti P, Abrams DB, Litt M, Hester R. Cognitive-Behavioral Coping Skills Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals With Alcohol Abuse and Dependence. Vol 3. Rockville, Md: National Institute on Alcohol Abuse and Alcoholism; 1994. Mattson ME, ed. Project MATCH Monograph Series.
29. Project MATCH Research Group. Matching alcoholism treatments to client heterogenetics: Project MATCH posttreatment drinking outcomes. J Stud Alcohol. 1997;58:7-29.
30. Skinner HA, Allen BA. Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol. 1982;91:199-209.
31. Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the alcohol timeline followback when administered by telephone and by computer. Drug Alcohol Depend. 1996;42:49-54.
32. Anton RF, Moak DH, Latham P. The obsessive compulsive drinking scale: a selfrated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995;19:92-99.
33. Frezza M, DiPadova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women: the role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med. 1990;332:95-99.
34. June HL, Grey C, Warren-Reese C, Ourr L, Ricks-Cord A, Johnson A, McCane S, Williams L, Mason D, Cummings R, Lawrence A. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred wistar rats. Alcohol Clin Exp Res. 1998;22:2174-2185.
35. Schluger JH, Ho A, Borg L, Porter M, Maniar S, Gundez M, Perret G, King A, Kreek MJ. Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications lor the treatment of alcoholism. Alcohol Clin Exp Res. 1998;22:1430-1436.
36. Ahmed SH, Koob GF. Transition from moderate to excessive drug intake: change in hedonic set point. Science. 1998;282:298-300.
37. Ho AKS, Chen RCA, Morrison JM. Interactions of narcotics, narcotic antagonists, and ethanol during acute, chronic, and withdrawal states. Ann N Y Acad Sci. 1976;281:297-310.
38. Volpicelli JR, Ulm RR, Hopson N. Alcohol drinking in rats during and following morphine injections. Alcohol. 1991;8:289-292.
39. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP. Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry. 1995;152:613-615.
40. Swift RM. Effect of naltrexone on human alcohol consumption. J Clin Psychiatry. 1995;57:24-29.
41. Koob GF, Nestler EJ. The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci. 1997;9:482-497.